Loss of MiR-155 Sensitizes FLT3-ITD+AML to Chemotherapy and FLT3 Inhibitors via Glycolysis Blocking by Targeting PIK3R1

FLT3 tyrosine kinase inhibitors in combination with chemotherapy have shown some success in patients with FLT3 mutations. But a variety of mechanisms have led to the rapid resistance to the treatment. One of the most prominent is the metabolic alteration on aerobic glycolysis. We aim to explore the role of a high expressing microRNA, miR-155, in mediating resistance to chemotherapy and FLT3 inhibitor treatment. The deep sequencing data mining revealed the connection between glycolysis and drug resistance. MV411 cells with miR-155 knockout (KO) not only had increased sensitivity to FLT3 inhibitors but also Adriamycin (ADM) treatment. When combined with glycolysis inhibition the treatment response in MV411 cells further increased. Whereas in miR-155 KO cells, a lower glucose consumption level and lactic acid level were observed, and western blotting showed a decreased expression of key enzymes in glycolysis pathways. A negative correlation between PIK3R1 and miR-155 level can be observed in the sequencing data from FLT3-ITD+ AML patients. Moreover, luciferase reporter assay revealed that the 3'UTR of PIK3R1 mRNA can interact with the seed sequence of miR-155-5p. In conclusion, the loss of miR-155 increased treatment sensitivity to both chemotherapy and FLT3 inhibitors in FLT3-ITD+ AML cells via glycolysis blocking by targeting PIK3R1.

[1]  X. Shuai,et al.  The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia , 2019, Scientific Reports.

[2]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[3]  J. Burke.  Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. , 2018, Molecular cell.

[4]  E. Estey,et al.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[5]  L. di Lisio,et al.  Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. , 2018, Blood.

[6]  Sinae Kim,et al.  microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer , 2018, Oncogene.

[7]  Nicholas S. Akins,et al.  Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer , 2018, Current topics in medicinal chemistry.

[8]  T. Wei,et al.  Suppression of Tumor Energy Supply by Liposomal Nanoparticle-Mediated Inhibition of Aerobic Glycolysis. , 2018, ACS applied materials & interfaces.

[9]  A. Bockisch,et al.  Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability , 2017, Journal of Translational Medicine.

[10]  L. Cantley,et al.  PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α , 2017, Proceedings of the National Academy of Sciences.

[11]  Ryan M. O’Connell,et al.  miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. , 2017, Blood.

[12]  E. Abel,et al.  SWELL1 is a regulator of adipocyte size, insulin signaling and glucose homeostasis , 2017, Nature Cell Biology.

[13]  S. Raimondi,et al.  miR‐155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group , 2016, Pediatric blood & cancer.

[14]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[15]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[16]  R. Montironi,et al.  Metabolic phenotype of bladder cancer. , 2016, Cancer treatment reviews.

[17]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[18]  S. Inoue,et al.  Genomic Classification in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[19]  Gang Liu,et al.  Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis. , 2015, American journal of respiratory and critical care medicine.

[20]  Yanqin Cao,et al.  Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling. , 2015, Immunobiology.

[21]  S. Ahn,et al.  Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. , 2015, Cancer letters.

[22]  Feng Zhang,et al.  Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.

[23]  William J. Israelsen,et al.  Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis , 2014, Cell.

[24]  D. Tenen,et al.  NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia , 2014, Leukemia.

[25]  E. Hirsch,et al.  PI3K in cancer–stroma interactions: bad in seed and ugly in soil , 2014, Oncogene.

[26]  M. Levis,et al.  The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond , 2014, Therapeutic advances in hematology.

[27]  Hui Zhou,et al.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data , 2013, Nucleic Acids Res..

[28]  Etienne Rouleau,et al.  PIK3R1 underexpression is an independent prognostic marker in breast cancer , 2013, BMC Cancer.

[29]  A. Myers.  New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway—The Devil Is in the Details , 2013, Clinical Cancer Research.

[30]  Guido Marcucci,et al.  Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[32]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[33]  Catherine C. Smith,et al.  The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[34]  M. Levis,et al.  Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors , 2013, Leukemia.

[35]  Yong Li,et al.  A novel miR‐155/miR‐143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells , 2012, The EMBO journal.

[36]  Andrew Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[37]  M. Keating,et al.  Metabolic Alterations in Highly Tumorigenic Glioblastoma Cells , 2011, The Journal of Biological Chemistry.

[38]  B. Smith,et al.  FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. , 2011, Blood.

[39]  Hui Zhou,et al.  starBase: a database for exploring microRNA–mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data , 2010, Nucleic Acids Res..

[40]  D. Lipka,et al.  FLT3 as a therapeutic target in AML: still challenging after all these years. , 2010, Blood.

[41]  M. Caligiuri,et al.  FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[42]  Ji Luo,et al.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. , 2010, Cancer research.

[43]  Matthew D. Ringel,et al.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors , 2010, Molecular and Cellular Endocrinology.

[44]  B. Vanhaesebroeck,et al.  The emerging mechanisms of isoform-specific PI3K signalling , 2010, Nature Reviews Molecular Cell Biology.

[45]  P. Zarrinkar,et al.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.

[46]  C. Croce,et al.  Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. , 2009, Blood.

[47]  N. Gray,et al.  FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[48]  D. Small.  Targeting FLT3 for the treatment of leukemia. , 2008, Seminars in hematology.

[49]  Hua Yu,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Hypoxia-Inducible Factor-1α RNA Expression in Both Tumor Cells and Tumor-Associated Myeloid Cells , 2008, Molecular Cancer Research.

[50]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[51]  Anton J. Enright,et al.  microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. , 2007, Immunity.

[52]  Peng Huang,et al.  The Warburg effect and its cancer therapeutic implications , 2007, Journal of bioenergetics and biomembranes.

[53]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[54]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Hofker.  Faculty Opinions recommendation of PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. , 2003 .

[56]  C. Thompson,et al.  Phosphatidylinositol 3-Kinase/Akt Signaling Is Neither Required for Hypoxic Stabilization of HIF-1α nor Sufficient for HIF-1-dependent Target Gene Transcription* , 2002, The Journal of Biological Chemistry.

[57]  A. Giaccia,et al.  Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. , 2001, Cancer research.